A Study to Evaluate the Safety Tolerability and Immunogenicity of a Modified RNA Vaccine Against Influenza

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Influenza
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants who can provide written informed consent
    2. Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures
    3. Healthy participants who are determined by medical history, physical examination(if required), and clinical judgment of the investigator to be eligible for inclusion in the study
    4. Male participant who is able to father children and willing to use an acceptable method of contraception as outlined in this protocol for at least 28 days after the last dose of study intervention; or female participant not of childbearing potential; or male participant not able to father children

You may not be eligible for this study if the following are true:

    1. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study
    2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
    3. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
    4. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
    5. Women who are pregnant or breastfeeding
    6. Allergy to egg proteins (egg or egg products) or chicken proteins
    7. Any participant who has had significant exposure to someone with laboratory-confirmed SARS-CoV-2 infection, COVID-19, or influenza in the past 14 days known prior to Visit 1
    8. Any participant who has a SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to Visit 1 that has not been confirmed as negative
    9. Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids
    10. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
    11. Vaccination with any influenza vaccine within 6 months (175 days) before study intervention administration
    12. Any participant who has received or plans to receive a modRNA-platform SARS-CoV-2 vaccine within 60 days of Visit 1
    13. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation
    14. History of heart disease



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.